Dr Friedlander on Emerging Agents of Interest in Urothelial Cancer
Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.
Terence W. Friedlander, MD, discusses emerging agents of interest in urothelial carcinoma.
Gotistobart plus pembrolizumab demonstrated antitumor activity and a manageable safety profile in platinum-resistant ovarian cancer.
Multiple Myeloma & CAR-T Cell Therapy Multiple Myeloma & CAR-T Cell Therapy Saad Usmani, MD, MBA, FACP Hematologic Oncologist Chief, Myeloma Service Memorial Sloan Kettering…
Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management…
Prices are based on membership status. Once logged in, the correct registration rate will automatically populate. Registration Type Early Bird Price (October 7, 2024 –…
An abstract is unavailable.
Illuccix has been approved in Canada for the selection of patients with mCRPC eligible for treatment with PSMA1-targeted radionuclide therapy.
Andrew Chapman and Kuang-Yi Wen of Thomas Jefferson University were named scientific awardees for their work in geriatric oncology research.
The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the…
ELVN-001 generated prolonged signals of clinical activity with a tolerable safety profile in patients with TKI-relapsed, -refractory, or -intolerant CML.
Patients, pathologists, clinicians, researchers, radiologists and others from around the world recently gathered for the 2024 International Invasive Lobular Carcinoma Symposium, in Leuven, Belgium.